Emcure Pharma Q4 Net Profit Jumps 24% to ₹244 Cr; Recommends ₹3.60 Dividend

Synopsis: Emcure Pharmaceuticals Ltd reported a strong Q4 FY26 performance with steady growth in revenue and profitability. The company also maintained healthy margins, supported by strong international business and operational efficiency. 

Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical company with a strong global presence. The company operates across multiple therapeutic segments and has a diversified footprint in domestic as well as international markets, including Europe, Canada, and emerging markets. 

Emcure Pharmaceuticals’ stock is currently trading around Rs. 1,687 declined by 5.80% compared to their previous day close of Rs. 1,793, with a market capitalization of approximately Rs. 32,169 crore. The stock witnessed some selling pressure and declined over 5% intraday, despite strong Q4 results. 

For the quarter ended March 2026, Emcure reported revenue from operations of Rs. 2,470 crore, registering a growth of 16.7% YoY compared to Rs. 2,116 crore in Q4 FY25. The growth was driven by strong traction in international markets and stable domestic demand. The company reported a gross profit of Rs. 1,467 crore, with gross margins improving to around 59.4%, reflecting better product mix and pricing strength. 

At the operating level, EBITDA stood at Rs. 485 crore, marking a strong growth of 24.4% YoY, while EBITDA margins expanded to 19.7%. Profit before tax (PBT) came in at Rs. 341 crore, up significantly from Rs. 261 crore in the same quarter last year. 

The company reported a net profit (PAT) of Rs. 244 crore, registering a 23.6% YoY growth compared to Rs. 197 crore in Q4 FY25. Adjusted profit after tax stood at Rs. 279 crore, showing an even stronger growth of 36% YoY, indicating underlying strength in core operations.

On a sequential basis, Emcure delivered steady growth in Q4 FY26 compared to Q3 FY26. Revenue increased from Rs. 2,363 crore in Q3 to Rs. 2,470 crore in Q4, reflecting a growth of around 4.5%, supported by improved sales across key geographies. 

Profitability also improved during the quarter, with net profit rising from Rs. 231 crore in Q3 to Rs. 244 crore in Q4, indicating better operational performance. EBITDA increased from Rs. 460 crore in Q3 to Rs. 485 crore in Q4, while margins expanded slightly from 19.5% to 19.7%, showing consistent execution and cost control. 

In addition to its strong Q4 performance, Emcure Pharmaceuticals has recommended a final dividend of Rs. 3.60 per equity share (36%) with a face value of Rs. 10 for the financial year ended March 31, 2026. The dividend is subject to approval by shareholders at the upcoming Annual General Meeting (AGM). 

Emcure Pharmaceuticals delivered a solid Q4 FY26 performance with strong revenue growth and improving profitability. The company’s focus on international markets, coupled with margin expansion, continues to support its growth trajectory. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing. 

The post Emcure Pharma Q4 Net Profit Jumps 24% to ₹244 Cr; Recommends ₹3.60 Dividend appeared first on Trade Brains.